Yapay Zeka Hızlı Bakış & Çıkarımlar
AI InsightIn our study, no differences were found in the serum levels of visfatin between patients with sarcoidosis and the control group.
📌 3 Maddede Bu Makale
Özet
OBJECTIVES: Sarcoidosis is a chronic systemic inflammatory disease that affects multiple organ systems. The role of biomarkers in thediagnosis and prognosis of sarcoidosis is increasing. Interest in the role of adipose tissue-mediated inflammation in the pathogenesisof inflammatory diseases has increased in recent years. Visfatin is a proinflammatory adipocytokine that has been studied for severalinflammatory diseases such as diabetes mellitus, obesity, and metabolic syndrome. We aimed to assess serum visfatin levels in sarcoidosis and its relationship with other markers of inflammation such as C-reactive protein (CRP), angiotensin-converting enzyme (ACE) anderythrocyte sedimentation rate (ESR).MATERIALS AND METHODS: We enrolled 59 patients with sarcoidosis and 21 healthy controls and measured plasma levels of visfatin,along with serum CRP, ESR, and ACE using ELISA (enzyme-linked immunosorbent assay) kits (Blue Gene Biotech, Shanghai, China).RESULTS: Visfatin levels did not differ significantly between the patients and control subjects (29.9±15.8 ng/mL for patients and23.93±16.73 ng/mL for controls, p=0.15), and there was no correlation between visfatin and serum CRP, ACE, or ESR in patients withsarcoidosis.CONCLUSION: Visfatin is recently being discussed as a biomarker for inflammatory diseases in several studies, and results are controversial. In our study, no differences were found in the serum levels of visfatin between patients with sarcoidosis and the control group.